Dépôt numérique
RECHERCHER

Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors

Téléchargements

Téléchargements par mois depuis la dernière année

Plus de statistiques...

El-Far, Mohamed; Kouassi, Pascale; Sylla, Mohamed; Zhang, Yuwei; Fouda, Ahmed; Fabre, Thomas; Goulet, Jean-Philippe; van Grevenynghe, Julien ORCID logoORCID: https://orcid.org/0000-0002-2952-4081; Lee, Terry; Singer, Joel; Harris, Marianne; Baril, Jean-Guy; Trottier, Benoit; Ancuta, Petronela; Routy, Jean-Pierre; Bernard, Nicole et Tremblay, Cécile (2016). Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors Scientific Reports , vol. 6 , nº 22902. pp. 1-18. DOI: 10.1038/srep22902.

[thumbnail of el far.pdf]
Prévisualisation
PDF - Version publiée
Disponible sous licence Creative Commons Attribution.

Télécharger (2MB) | Prévisualisation
[thumbnail of Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected.pdf]
Prévisualisation
PDF - Matériel supplémentaire
Disponible sous licence Creative Commons Attribution.

Télécharger (4MB) | Prévisualisation

Résumé

HIV-infected slow progressors (SP) represent a heterogeneous group of subjects who spontaneously control HIV infection without treatment for several years while showing moderate signs of disease progression. Under conditions that remain poorly understood, a subgroup of these subjects experience failure of spontaneous immunological and virological control. Here we determined the frequency of SP subjects who showed loss of HIV control within our Canadian Cohort of HIV(+) Slow Progressors and identified the proinflammatory cytokine IL-32 as a robust biomarker for control failure. Plasmatic levels of the proinflammatory isoforms of IL-32 (mainly beta and gamma) at earlier clinic visits positively correlated with the decline of CD4 T-cell counts, increased viral load, lower CD4/CD8 ratio and levels of inflammatory markers (sCD14 and IL-6) at later clinic visits. We present here a proof-of-concept for the use of IL-32 as a predictive biomarker for disease progression in SP subjects and identify IL-32 as a potential therapeutic target.

Type de document: Article
Mots-clés libres: Adult; Antigens, CD14/blood/genetics; Biomarkers/ blood; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cells, Cultured; Cohort Studies; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Profiling/methods; HIV Infections/ blood/genetics/immunology; HIV-1/immunology; Humans; Inflammation Mediators/ blood; Interleukin-6/blood/genetics; Interleukins/ blood/genetics; Male; Oligonucleotide Array Sequence Analysis; Protein Isoforms/blood/genetics; Viral Load/immunology
Centre: Centre INRS-Institut Armand Frappier
Date de dépôt: 24 juin 2017 07:10
Dernière modification: 16 févr. 2022 15:43
URI: https://espace.inrs.ca/id/eprint/5503

Gestion Actions (Identification requise)

Modifier la notice Modifier la notice